Friday, August 25, 2023
Fresenius Kabi and Lupagen Inc. have unveiled their strategic partnership and supply agreement with the aim of revolutionizing the delivery of cell and gene therapies directly to patients at their bedside.
Cell and gene therapies hold significant promise for addressing a range of conditions, including cancers, autoimmune disorders, hematologic diseases, and rare illnesses. Despite their potential, challenges such as lengthy manufacturing processes, complex logistics, and high costs have hindered wider patient access to these therapies.
The collaboration leverages Fresenius Kabi's specialized expertise in apheresis collection and automated cell processing technology. This partnership will play a pivotal role in advancing Lupagen's Extracorporeal Cell and Gene Therapy Delivery System. The main objective of this system is to streamline the delivery of cell and gene therapies, making it more cost-effective and convenient through bedside administration. The agreement encompasses both the development of novel technologies and ensuring a seamless supply chain.
Bryan Blickhan, Senior Vice President of R&D and Device Production, Transfusion Medicine, and Cell Therapies at Fresenius Kabi, emphasized the significance of this partnership, stating, "Cell and gene therapies have demonstrated their potential in treating complex diseases. This partnership marks a significant step towards making these therapies more accessible and feasible, ultimately enabling bedside treatments."
Nipon Das, M.D., Co-founder, and CEO of Lupagen, also conveyed his excitement, expressing, "Lupagen's vision is to democratize cell and gene therapy, making them as accessible as routine blood transfusions or dialysis procedures. Our collaboration with Fresenius Kabi, a global leader in blood and cell technologies, accelerates the realization of this vision, ensuring that patients who urgently require these transformative therapies can readily receive them."